Is XRAY or CERS more profitable?

Cerus has a net margin of -3.06% compared to DENTSPLY SIRONA's net margin of -14.99%. DENTSPLY SIRONA's return on equity of 20.84% beat Cerus' return on equity. Company Net Margins Return on Equity Return on Assets DENTSPLY SIRONA -14.99% 20.84% 5.32% Cerus -3.06% -10.19% -3.14%

Do analysts recommend CERS or AVNS?

Cerus currently has a consensus price target of $5.25, indicating a potential upside of 132.30%. Given Cerus' stronger consensus rating and higher probable upside, research analysts clearly believe Cerus is more favorable than Avanos Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cerus 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Avanos Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is CERS or AVNS more profitable?

Cerus has a net margin of -3.06% compared to Avanos Medical's net margin of -10.39%. Avanos Medical's return on equity of 5.39% beat Cerus' return on equity. Company Net Margins Return on Equity Return on Assets Cerus -3.06% -10.19% -3.14% Avanos Medical -10.39% 5.39% 3.97%

Is CERS or QDEL more profitable?

Cerus has a net margin of -3.06% compared to QuidelOrtho's net margin of -39.20%. QuidelOrtho's return on equity of 4.88% beat Cerus' return on equity. Company Net Margins Return on Equity Return on Assets Cerus -3.06% -10.19% -3.14% QuidelOrtho -39.20% 4.88% 1.63%

Which has better valuation and earnings, EMBC or CERS?

Embecta has higher revenue and earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Embecta $1.08B 0.33 $95.40M $1.48 4.19 Cerus $206.13M 2.21 -$15.63M -$0.03 N/A

Is EMBC or CERS more profitable?

Embecta has a net margin of 8.59% compared to Cerus' net margin of -3.06%. Cerus' return on equity of -10.19% beat Embecta's return on equity. Company Net Margins Return on Equity Return on Assets Embecta 8.59% -19.25% 10.82% Cerus -3.06% -10.19% -3.14%

Which has higher valuation and earnings, CERS or SMTI?

Cerus has higher revenue and earnings than Sanara MedTech. Cerus is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cerus $206.13M 2.21 -$15.63M -$0.03 N/A Sanara MedTech $103.12M 3.13 -$37.56M -$3.59 N/A

Is CERS or SMTI more profitable?

Cerus has a net margin of -3.06% compared to Sanara MedTech's net margin of -29.15%. Sanara MedTech's return on equity of 29.72% beat Cerus' return on equity. Company Net Margins Return on Equity Return on Assets Cerus -3.06% -10.19% -3.14% Sanara MedTech -29.15% 29.72% 2.84%

Cerus (CERS) Competitors

$2.26 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$2.26 0.00 (-0.22%)

As of 07:30 PM Eastern

Compare

CERS vs. XRAY, AVNS, QDEL, EMBC, and SMTI

Should you buy Cerus stock or one of its competitors? Cerus's main competitors and comparable companies include DENTSPLY SIRONA (XRAY), Avanos Medical (AVNS), QuidelOrtho (QDEL), Embecta (EMBC), and Sanara MedTech (SMTI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare supplies" industry.

How does Cerus compare to DENTSPLY SIRONA?

DENTSPLY SIRONA (NASDAQ:XRAY) and Cerus (NASDAQ:CERS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

DENTSPLY SIRONA presently has a consensus target price of $13.17, suggesting a potential upside of 54.72%. Cerus has a consensus target price of $5.25, suggesting a potential upside of 132.30%. Given Cerus' stronger consensus rating and higher possible upside, analysts clearly believe Cerus is more favorable than DENTSPLY SIRONA.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DENTSPLY SIRONA	3 Sell rating(s)	7 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cerus	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

DENTSPLY SIRONA has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market. Comparatively, Cerus has a beta of 1.83, meaning that its stock price is 83% more volatile than the broader market.

Cerus has lower revenue, but higher earnings than DENTSPLY SIRONA. Cerus is trading at a lower price-to-earnings ratio than DENTSPLY SIRONA, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DENTSPLY SIRONA	$3.68B	0.46	-$598M	-$2.75	N/A
Cerus	$206.13M	2.21	-$15.63M	-$0.03	N/A

Cerus has a net margin of -3.06% compared to DENTSPLY SIRONA's net margin of -14.99%. DENTSPLY SIRONA's return on equity of 20.84% beat Cerus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DENTSPLY SIRONA	-14.99%	20.84%	5.32%
Cerus	-3.06%	-10.19%	-3.14%

In the previous week, DENTSPLY SIRONA had 10 more articles in the media than Cerus. MarketBeat recorded 11 mentions for DENTSPLY SIRONA and 1 mentions for Cerus. Cerus' average media sentiment score of 1.02 beat DENTSPLY SIRONA's score of 0.37 indicating that Cerus is being referred to more favorably in the news media.

Company	Overall Sentiment
DENTSPLY SIRONA	Neutral
Cerus	Positive

95.7% of DENTSPLY SIRONA shares are held by institutional investors. Comparatively, 78.4% of Cerus shares are held by institutional investors. 0.5% of DENTSPLY SIRONA shares are held by insiders. Comparatively, 5.3% of Cerus shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Cerus beats DENTSPLY SIRONA on 9 of the 15 factors compared between the two stocks.

How does Cerus compare to Avanos Medical?

Cerus (NASDAQ:CERS) and Avanos Medical (NYSE:AVNS) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Cerus has a net margin of -3.06% compared to Avanos Medical's net margin of -10.39%. Avanos Medical's return on equity of 5.39% beat Cerus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cerus	-3.06%	-10.19%	-3.14%
Avanos Medical	-10.39%	5.39%	3.97%

78.4% of Cerus shares are owned by institutional investors. Comparatively, 95.2% of Avanos Medical shares are owned by institutional investors. 5.3% of Cerus shares are owned by insiders. Comparatively, 2.3% of Avanos Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Cerus had 1 more articles in the media than Avanos Medical. MarketBeat recorded 1 mentions for Cerus and 0 mentions for Avanos Medical. Cerus' average media sentiment score of 1.02 beat Avanos Medical's score of 0.00 indicating that Cerus is being referred to more favorably in the media.

Company	Overall Sentiment
Cerus	Positive
Avanos Medical	Neutral

Cerus currently has a consensus price target of $5.25, indicating a potential upside of 132.30%. Given Cerus' stronger consensus rating and higher probable upside, research analysts clearly believe Cerus is more favorable than Avanos Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerus	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Avanos Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Cerus has higher earnings, but lower revenue than Avanos Medical. Cerus is trading at a lower price-to-earnings ratio than Avanos Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerus	$206.13M	2.21	-$15.63M	-$0.03	N/A
Avanos Medical	$715.90M	1.64	-$72.90M	-$1.61	N/A

Cerus has a beta of 1.83, indicating that its share price is 83% more volatile than the broader market. Comparatively, Avanos Medical has a beta of 1.57, indicating that its share price is 57% more volatile than the broader market.

Summary

Cerus beats Avanos Medical on 11 of the 16 factors compared between the two stocks.

How does Cerus compare to QuidelOrtho?

Cerus (NASDAQ:CERS) and QuidelOrtho (NASDAQ:QDEL) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

In the previous week, QuidelOrtho had 6 more articles in the media than Cerus. MarketBeat recorded 7 mentions for QuidelOrtho and 1 mentions for Cerus. Cerus' average media sentiment score of 1.02 beat QuidelOrtho's score of 0.46 indicating that Cerus is being referred to more favorably in the media.

Company	Overall Sentiment
Cerus	Positive
QuidelOrtho	Neutral

Cerus has a net margin of -3.06% compared to QuidelOrtho's net margin of -39.20%. QuidelOrtho's return on equity of 4.88% beat Cerus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cerus	-3.06%	-10.19%	-3.14%
QuidelOrtho	-39.20%	4.88%	1.63%

Cerus has a beta of 1.83, suggesting that its share price is 83% more volatile than the broader market. Comparatively, QuidelOrtho has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market.

78.4% of Cerus shares are owned by institutional investors. Comparatively, 99.0% of QuidelOrtho shares are owned by institutional investors. 5.3% of Cerus shares are owned by company insiders. Comparatively, 1.1% of QuidelOrtho shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cerus has higher earnings, but lower revenue than QuidelOrtho. Cerus is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerus	$206.13M	2.21	-$15.63M	-$0.03	N/A
QuidelOrtho	$2.73B	0.35	-$1.13B	-$15.41	N/A

Cerus currently has a consensus target price of $5.25, indicating a potential upside of 132.30%. QuidelOrtho has a consensus target price of $13.63, indicating a potential downside of 3.37%. Given Cerus' stronger consensus rating and higher probable upside, research analysts plainly believe Cerus is more favorable than QuidelOrtho.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerus	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
QuidelOrtho	2 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Cerus beats QuidelOrtho on 10 of the 16 factors compared between the two stocks.

How does Cerus compare to Embecta?

Embecta (NASDAQ:EMBC) and Cerus (NASDAQ:CERS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

Embecta presently has a consensus price target of $11.00, indicating a potential upside of 77.42%. Cerus has a consensus price target of $5.25, indicating a potential upside of 132.30%. Given Cerus' stronger consensus rating and higher probable upside, analysts clearly believe Cerus is more favorable than Embecta.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60
Cerus	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Embecta has higher revenue and earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.08B	0.33	$95.40M	$1.48	4.19
Cerus	$206.13M	2.21	-$15.63M	-$0.03	N/A

Embecta has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market. Comparatively, Cerus has a beta of 1.83, indicating that its share price is 83% more volatile than the broader market.

In the previous week, Embecta and Embecta both had 1 articles in the media. Embecta's average media sentiment score of 1.82 beat Cerus' score of 1.02 indicating that Embecta is being referred to more favorably in the media.

Company	Overall Sentiment
Embecta	Very Positive
Cerus	Positive

Embecta has a net margin of 8.59% compared to Cerus' net margin of -3.06%. Cerus' return on equity of -10.19% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Embecta	8.59%	-19.25%	10.82%
Cerus	-3.06%	-10.19%	-3.14%

93.8% of Embecta shares are held by institutional investors. Comparatively, 78.4% of Cerus shares are held by institutional investors. 1.3% of Embecta shares are held by company insiders. Comparatively, 5.3% of Cerus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Embecta beats Cerus on 8 of the 15 factors compared between the two stocks.

How does Cerus compare to Sanara MedTech?

Cerus (NASDAQ:CERS) and Sanara MedTech (NASDAQ:SMTI) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

78.4% of Cerus shares are held by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are held by institutional investors. 5.3% of Cerus shares are held by insiders. Comparatively, 42.0% of Sanara MedTech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Cerus and Cerus both had 1 articles in the media. Cerus' average media sentiment score of 1.02 beat Sanara MedTech's score of 0.60 indicating that Cerus is being referred to more favorably in the media.

Company	Overall Sentiment
Cerus	Positive
Sanara MedTech	Positive

Cerus presently has a consensus target price of $5.25, suggesting a potential upside of 132.30%. Sanara MedTech has a consensus target price of $35.00, suggesting a potential downside of 0.40%. Given Cerus' stronger consensus rating and higher possible upside, analysts clearly believe Cerus is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerus	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Sanara MedTech	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Cerus has a net margin of -3.06% compared to Sanara MedTech's net margin of -29.15%. Sanara MedTech's return on equity of 29.72% beat Cerus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cerus	-3.06%	-10.19%	-3.14%
Sanara MedTech	-29.15%	29.72%	2.84%

Cerus has higher revenue and earnings than Sanara MedTech. Cerus is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerus	$206.13M	2.21	-$15.63M	-$0.03	N/A
Sanara MedTech	$103.12M	3.13	-$37.56M	-$3.59	N/A

Cerus has a beta of 1.83, meaning that its stock price is 83% more volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market.

Summary

Cerus beats Sanara MedTech on 10 of the 15 factors compared between the two stocks.

Get Cerus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CERS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CERS vs. The Competition

Export

Metric	Cerus	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$455.45M	$5.58B	$7.27B	$13.21B
Dividend Yield	N/A	1.75%	2.52%	22.89%
P/E Ratio	-75.33	19.92	193.55	19.04
Price / Sales	2.21	67.33	561.79	81.57
Price / Cash	N/A	32.25	77.16	53.04
Price / Book	6.65	5.86	10.71	6.03
Net Income	-$15.63M	$146.14M	$3.50B	$380.34M
7 Day Performance	-3.42%	-1.23%	-3.18%	-3.04%
1 Month Performance	-9.24%	-3.00%	-6.61%	-5.16%
1 Year Performance	44.87%	1.97%	3.69%	-2.48%

Cerus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CERS Cerus	2.3092 of 5 stars	$2.26 flat	$5.25 +132.3%	+41.3%	$455.45M	$206.13M	N/A	345
XRAY DENTSPLY SIRONA	4.0283 of 5 stars	$8.60 +0.4%	$13.31 +54.8%	-27.9%	$1.72B	$3.68B	N/A	14,000
AVNS Avanos Medical	0.0535 of 5 stars	$24.99 flat	N/A	N/A	$1.17B	$715.90M	N/A	4,040
QDEL QuidelOrtho	1.6434 of 5 stars	$12.40 +2.1%	$13.63 +9.9%	-49.8%	$852.46M	$2.73B	N/A	6,500	News Coverage
EMBC Embecta	4.0454 of 5 stars	$6.04 +2.6%	$11.00 +82.3%	-55.2%	$341.94M	$1.08B	4.08	1,850	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CERS) was last updated on 10/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cerus (CERS) Competitors

CERS vs. XRAY, AVNS, QDEL, EMBC, and SMTI

How does Cerus compare to DENTSPLY SIRONA?

Summary

How does Cerus compare to Avanos Medical?

Summary

How does Cerus compare to QuidelOrtho?

Summary

How does Cerus compare to Embecta?

Summary

How does Cerus compare to Sanara MedTech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CERS vs. The Competition

Cerus Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cerus (CERS) Competitors

CERS vs. XRAY, AVNS, QDEL, EMBC, and SMTI

How does Cerus compare to DENTSPLY SIRONA?

Do analysts rate XRAY or CERS?

Which has more risk and volatility, XRAY or CERS?

Which has better earnings and valuation, XRAY or CERS?

Is XRAY or CERS more profitable?

Does the media refer more to XRAY or CERS?

Do insiders and institutionals hold more shares of XRAY or CERS?

Summary

How does Cerus compare to Avanos Medical?

Is CERS or AVNS more profitable?

Do institutionals & insiders believe in CERS or AVNS?

Does the media prefer CERS or AVNS?

Do analysts recommend CERS or AVNS?

Which has stronger earnings & valuation, CERS or AVNS?

Which has more volatility and risk, CERS or AVNS?

Summary

How does Cerus compare to QuidelOrtho?

Does the media prefer CERS or QDEL?

Is CERS or QDEL more profitable?

Which has more risk and volatility, CERS or QDEL?

Do institutionals and insiders believe in CERS or QDEL?

Which has stronger earnings and valuation, CERS or QDEL?

Do analysts prefer CERS or QDEL?

Summary

How does Cerus compare to Embecta?

Do analysts rate EMBC or CERS?

Which has better valuation and earnings, EMBC or CERS?

Which has more risk and volatility, EMBC or CERS?

Does the media refer more to EMBC or CERS?

Is EMBC or CERS more profitable?

Do institutionals and insiders have more ownership in EMBC or CERS?

Summary

How does Cerus compare to Sanara MedTech?

Do insiders and institutionals have more ownership in CERS or SMTI?

Does the media favor CERS or SMTI?

Do analysts rate CERS or SMTI?

Is CERS or SMTI more profitable?

Which has higher valuation and earnings, CERS or SMTI?

Which has more risk and volatility, CERS or SMTI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CERS vs. The Competition

Cerus Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools